BioWorld

Nov. 13, 2007

View Archived Issues

As Big Pharma Model Falters, Biotech Rides To The Rescue

Read More

New Virulence Determinant Of Community-Associated MRSA

Read More

Infinity Regains Hedgehog Pathway Inhibitor Program

Read More

Molecular Insight Bond Deal: $150M To Advance Pipeline

Read More

Other News To Note

Read More

Synta's Elesclomol In Pivotal Study In Melanoma Patients

A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today) Read More

Clinic Roundup

Read More

ACAAI Roundup

Read More